{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aimovig",
    "query": {
      "intervention": "Aimovig"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 45,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aimovig&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T15:04:14.654Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06212661",
      "title": "Migraine Medication Effects on Urinary Symptoms",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overactive Bladder",
        "Bladder Pain Syndrome",
        "Migraine Disorders",
        "Overactive Bladder Syndrome",
        "Overactive Detrusor",
        "Migraine",
        "Interstitial Cystitis"
      ],
      "interventions": [
        {
          "name": "Ubrogepant",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant",
          "type": "DRUG"
        },
        {
          "name": "Atogepant",
          "type": "DRUG"
        },
        {
          "name": "Eptinezumab",
          "type": "DRUG"
        },
        {
          "name": "Fremanezumab",
          "type": "DRUG"
        },
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Botulinum toxin A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2024-04-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06212661"
    },
    {
      "nct_id": "NCT07159750",
      "title": "Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Migraine",
        "Episodic Migraine",
        "Chronic Migraine, Headache"
      ],
      "interventions": [
        {
          "name": "CGRP antibody or gepant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital Universitari Vall d'Hebron Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2024-01-02",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07159750"
    },
    {
      "nct_id": "NCT02066415",
      "title": "A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Treatment for Prevention of Chronic Migraine"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 667,
      "start_date": "2014-03-05",
      "completion_date": "2016-04-28",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 34,
      "location_summary": "La Jolla, California • Newport Beach, California • San Francisco, California + 30 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02066415"
    },
    {
      "nct_id": "NCT02456740",
      "title": "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 955,
      "start_date": "2015-07-17",
      "completion_date": "2017-06-19",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 59,
      "location_summary": "Phoenix, Arizona • Anaheim, California • Encino, California + 55 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02456740"
    },
    {
      "nct_id": "NCT02174861",
      "title": "A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Treatment for Prevention of Chronic Migraine"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 609,
      "start_date": "2014-06-30",
      "completion_date": "2017-05-26",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 29,
      "location_summary": "Newport Beach, California • Palo Alto, California • Santa Monica, California + 25 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02174861"
    },
    {
      "nct_id": "NCT04461795",
      "title": "Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David True",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-12-01",
      "completion_date": "2022-01-10",
      "has_results": true,
      "last_update_posted_date": "2022-04-13",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 2,
      "location_summary": "City of Saint Peters, Missouri • Springfield, Missouri",
      "locations": [
        {
          "city": "City of Saint Peters",
          "state": "Missouri"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04461795"
    },
    {
      "nct_id": "NCT01890109",
      "title": "Study of Erenumab (AMG 334) in Women With Hot Flashes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Vasomotor Symptoms; Hot Flashes"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 65 Years · Female only"
      },
      "enrollment_count": 103,
      "start_date": "2013-05-13",
      "completion_date": "2014-03-11",
      "has_results": true,
      "last_update_posted_date": "2019-01-14",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Miami, Florida • Winston-Salem, North Carolina + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01890109"
    },
    {
      "nct_id": "NCT05177406",
      "title": "Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Aimovig",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1839,
      "start_date": "2020-08-31",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-01-04",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05177406"
    },
    {
      "nct_id": "NCT02575833",
      "title": "Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stable Angina"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 89,
      "start_date": "2015-11-23",
      "completion_date": "2017-04-13",
      "has_results": true,
      "last_update_posted_date": "2018-08-24",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 8,
      "location_summary": "Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02575833"
    },
    {
      "nct_id": "NCT04884763",
      "title": "Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Temporomandibular Disorder"
      ],
      "interventions": [
        {
          "name": "Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments",
          "type": "DRUG"
        },
        {
          "name": "Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-11-15",
      "completion_date": "2024-01-04",
      "has_results": true,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-09-27T15:04:14.654Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04884763"
    }
  ]
}